ESG

The pediatric device firm posted 15% growth to $236.1M in 2025, issuing strong 2026 guidance fueled by its specialty bracing and European expansion.

A new clinical trial for AB001, a potent alpha radioligand therapy, offers hope for patients with advanced prostate cancer, including those resistant to current treatments.

With FDA alignment for its rapid postpartum depression therapy and new trials for anxiety, Reunion Neuroscience is pioneering a new era of mental health.

KEY Investment Partners acquires BellRock Brands' portfolio out of receivership, launching MM Brands with Joe Bayern to lead a wellness-focused revival.

Annexon is poised for a landmark year with potential first-in-class drugs for GBS and GA, promising to reset treatment standards and offer new hope.

WindRose and Francisco Partners invest in Avalon, signaling a major shift toward tech-driven management of the multi-billion dollar diagnostic testing market.

With pivotal cancer drug data looming and a new nuclear supply chain, Bicycle Therapeutics is betting big on its novel platform. Will 2026 be its breakout year?

Princeton-based EDETEK will present its AI-powered clinical trial ecosystem at the J.P. Morgan conference, aiming to capture a slice of a booming market.

With a key FDA filing and pivotal data on the horizon, Pharvaris aims to redefine HAE treatment with its convenient, rapid-acting oral therapy.

Amidst a strategic push for profitability, CytoSorbents advances its DrugSorb-ATR device, aiming to revolutionize safety in cardiac surgery.

CoinEx's consistent token burning removes over 166M CET in a year, signaling a long-term commitment to scarcity and value in a competitive market.

Amid rising costs and market volatility, Malaysia's top SMEs are redefining success. The SME100 Awards reveal how innovation fuels their remarkable growth.

The food services giant is the only company in its sector to earn CDP's top climate rating, signaling a major shift in industry sustainability standards.

EfTEN Real Estate Fund reports its best-ever operating results, proposing an 8% dividend hike, while a minor portfolio revaluation hints at market shifts.

French aerospace giant Dassault Aviation partners with Harmattan AI, aiming to lead Europe's charge in the global race for sovereign, AI-driven warfare.

A CES newcomer is redefining solar power with rollable curtains and self-charging tech, aiming to weave green energy into the fabric of everyday life.

A federal plan for the Colorado River's future ignites fears of 'dramatic cuts' for 20 million Californians and threatens a multi-state legal war.

A federal court blocked Edwards Lifesciences' key acquisition, citing monopoly fears, yet the company's financial outlook surprisingly improves.

One year after devastating wildfires, many uninsured seniors are still displaced. Habitat LA's volunteer event highlights the long, arduous road to recovery.

With booming revenue, a potential blockbuster on the horizon, and key partnerships, Ascendis Pharma lays out a bold roadmap for global dominance.